Biological E Limited

Mahima Datla

Narender Dev Mantena

Ramesh Venkat Matur

Rajendar Burki

Rajan Sriraman

Vivek Babu Kandimalla

Akshay Goel

Veerapandu Sangareddy

Deviprasanna Chakka

Satyam Naidu Sureddi

Muthyala Venkateswara Reddy

Kantam Charan

Mandar Shirish Dixit

Ravi Ganapathy

Eswara Kowlakuntla

Santosh Renukuntla

Sreenivasa Rao Ganti

Swetha Kamireddy

Ravi Pratap Narayan Mishra

Vikram Madhusadan Paradkar

Manish Manohar

Nagireddy Gade

Yogesh Mishra

Krishnanand Tiwari

Tushar Joglekar

Balamurali Masilamani

Nagarajan Thirumeni

Ravi Pratap Mishra

Sureddisatyam Naidu

Vikram Madhusadan Paradkar Paradkar

Renukuntla Santosh

Kowlakuntla Eswara

The invention relates to capsular polysaccharides of. More specifically, the present invention relates to sized and purified capsular polysaccharides ofserotypes 2, 15A, 15C & 35B and process for their preparation.

Purified capsular polysaccharides of

The present invention relates to vaccine formulations comprising preservative systems. More particularly, the present invention relates to preservative systems for vaccine formulations which is free of thiomersal, and comprising 2-phenoxyethanol and at least one other preservative selected from m-cresol, benzyl alcohol, phenol and benzoic acid.

Vaccine formulations comprising preservative

The present invention provides a colorimetric based method for quantifying carbohydrates in a given aqueous sample. The method provided by the invention uses 2-Phenoxyethanol as a novel reagent for quantifying carbohydrates in a given sample. The present invention is a rapid, sensitive, simple and direct method for carbohydrate quantification.

Methods for quantification of carbohydrates

The present invention relates to expression of Pneumococcal Surface Protein A (PspA). The invention represents an advancement in the field of genetic engineering and vaccine technology. The invention discloses expression vectors and recombinant host cells for expression of truncated PspA peptide. The invention also discloses vaccine compositions comprising the truncated peptides as carrier protein.

Expression of pneumococcal surface protein a (PSPA)

The invention relates to a method for the removal of protein and other impurities from microbial capsular polysaccharides. More particularly, the present invention relates to isolation of microbial capsular polysaccharides in pure form after removal of protein and other impurities.

Method for separation of protein and other impurities from microbial capsular polysaccharides

The present disclosure relates to multivalent pneumococcal vaccine compositions comprising capsular pneumococcal polysaccharide serotypes each individually conjugated to carrier proteins. When conjugated, the combination of the capsular pneumococcal polysaccharide serotype and the carrier protein is referred to herein as a polysaccharide-protein conjugate. The pneumococcal vaccine compositions may further comprise one or more of the following; a pharmaceutically acceptable carrier, a pharmaceutically acceptable diluent, a buffer, a preservative, a stabilizer, an adjuvant, and/or a lyophilization excipient. Methods of making and administering the pneumococcal vaccine compositions described herein are also provided.

Multivalent pneumococcal vaccine compositions comprising polysaccharide-protein conjugates

The present invention relates to novel semi-synthetic meningococcal conjugate vaccine comprising novel synthetic oligosaccharide conjugated to a carrier protein. The present invention also relates to novel synthetic meningococcal oligosaccharide and a process for its preparation.

Semi-synthetic meningococcal conjugate vaccine

The present invention relates to a multivalent Pneumococcal conjugate vaccine (PCV) composition comprising: 1) at least 12 capsular polysaccharides selected from serotypes 1, 3, 4, 5, 6B, 7F, 9N, 9V, 15B, 14, 18C, 19A, 19F, 22F, 23F and 33F ofactivated with CDAP and conjugated to carrier protein selected from CRM, pneumococcal surface protein A (PspA), pneumococcal adhesin protein (PsaA) or combination thereof and 2) a pharmaceutically acceptable carrier, wherein the composition does not contain capsular polysaccharide from serotype 6A.

Multivalent pneumococcal conjugate vaccine

The present invention provides an improved method for the production of CRMwith high yield using engineeredstrain having an increased copy number of the CRMgene, wherein the method comprises growing the strain in media free of animal-derived components with one or more amino acids.

Method for high level production of CRM

The present invention relates to a preparation method which is performed by expressing the recombinant carrier proteins inand purification thereof. More particular, the invention relates to industrially scalable process for the recovery of recombinant carrier proteins.

Industrially scalable process for recovering biologically active recombinant carrier proteins

The present invention relates to an improved process for production of Aluminium phosphate (AlPhos) gel wherein the solutions of aluminium salt and alkaline phosphate salt are added to water by maintaining the pH under stirring to obtain the precipitate, followed by sterilization of the said precipitate and finally obtaining the Aluminum phosphate gel.

Method for preparation of aluminium phosphate gel for application in vaccine formulations

The present invention relates to high level expression of bacterial toxoid or toxin protein of pharmacological interest by means of an optimized novel polynucleotide sequence and host transformed with the said polynucleotide. Specifically, the invention provides a method for high production of polypeptide CRMwherein, the polynucleotide of the invention is used to transform a suitable host resulting in over-expression of corresponding proteins and a method for isolating the expressed polypeptide. More particularly, the present invention relates to high level expression of CRMinand a method for the isolation and purification thereof.

Growing community of inventors

Hyderabad Telangana, India

Mahima Datla